| Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 (NCT02433652) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-09-01 |
| Autologous Polyclonal Tregs for Lupus (NCT02428309) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-08-27 |
| Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART) (NCT02411539) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-08-25 |
| Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption (NCT02463227) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-08-01 |
| Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults (NCT02431767) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-08-01 |
| Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults (NCT02564575) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-08-01 |
| Natural History and Genetics of Food Allergy and Related Conditions (NCT02504853) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-07-29 |
| Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates (NCT02471378) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-07-28 |
| Xenodiagnosis After Antibiotic Treatment for Lyme Disease (NCT02446626) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-07-24 |
| Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment in Malian Children (NCT02504918) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-07-21 |
| Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B... (NCT02511054) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-07-21 |
| Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers (NCT02484417) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-07-21 |
| Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge (NCT02511002) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-07-17 |
| VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption (NCT02471326) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-07-13 |
| Rituximab and Belimumab for Lupus Nephritis (NCT02260934) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-07-09 |
| Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants (NCT02256631) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-06-30 |
| Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation (NCT02511041) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-06-30 |
| NIAID Clinical Center Genomics Opportunity Protocol (NCT02417766) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-06-29 |
| Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048 (NCT02419456) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-06-01 |
| A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine (NCT02251288) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-05-18 |
| Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin (NCT02348424) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-05-05 |
| Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048 (NCT02356302) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-05-01 |
| Registry for Asthma Characterization and Recruitment 2 (NCT02513264) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-04-14 |
| Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers (NCT02385123) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-04-01 |
| Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005) (NCT02450838) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-04-01 |
| Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents (NCT02213328) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-04-01 |
| Phase 1 Trial of Inactivated West Nile Virus Vaccine (NCT02337868) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-03-31 |
| VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults (NCT02408913) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-03-26 |
| Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults (NCT02344290) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-03-26 |
| Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection (NCT02363322) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-03-13 |
| Tocilizumab (TCZ) in New-onset Type 1 Diabetes (NCT02293837) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-03-12 |
| Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers (NCT02389192) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-03-11 |
| A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy (NCT02311413) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-03-09 |
| Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases (NCT02338986) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-03-04 |
| Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (NCT02237196) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-03-03 |
| Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults (NCT02392325) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-03-01 |
| Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model (NCT02371668) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-02-25 |
| NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis (NCT02371681) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-02-25 |
| Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss (NCT01649869) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-02-24 |
| A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults (NCT02337855) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-02-04 |
| A Safety and Immune Response Study of 2 Experimental HIV Vaccines (NCT02404311) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-02-02 |
| Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults (NCT02178800) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-02-01 |
| Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda (NCT02354404) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-01-27 |
| Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (NCT02140255) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-01-23 |
| B Cell Induction in Pediatric Lung Transplantation (NCT02266888) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-01-22 |
| Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) (NCT02344407) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-01-20 |
| Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali (NCT02334462) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-01-07 |
| Impact of Vaccination on Th2 Immunity in Infancy (NCT02213341) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-01-01 |
| Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza (NCT02287467) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-01-01 |
| Cat Pilot Study - Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC) (NCT02163122) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-01-01 |
| Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation (NCT02188719) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-12-17 |
| Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali (NCT02311387) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-12-05 |
| Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults (NCT02317900) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-12-01 |
| Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (NCT02330965) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-12-01 |
| Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults (NCT02296541) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-12-01 |
| Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea (NCT02257918) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-11-25 |
| Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole (NCT02234570) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-11-17 |
| Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB (NCT01751568) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-11-12 |
| Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand (NCT02332733) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-11-01 |
| Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide (NCT02282904) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-10-23 |
| Novel Genetic Disorders of the Immune System (NCT02257892) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-10-22 |
| Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome (NCT02231879) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-10-14 |
| Human Immunity Against Staphylococcus Aureus Skin Infection (NCT02262819) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-10-10 |
| H7N9 Mix and Match With MF59 in Healthy Elderly Persons (NCT02213354) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-10-01 |
| Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study (NCT02255123) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-10-01 |
| Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old (NCT02274545) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-10-01 |
| People Presenting With Neurocysticercosis in North America (NCT02233855) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-09-03 |
| Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis (NCT02190266) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-09-02 |
| Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children (NCT02237209) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-09-01 |
| Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children (NCT02040831) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-09-01 |
| Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age (NCT01975012) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-09-01 |
| Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults (NCT02231866) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-08-27 |
| Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women (NCT01494038) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-08-19 |
| Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection (NCT02225158) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-08-15 |
| Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children (NCT02182986) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-08-14 |
| Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects (NCT02178254) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-08-01 |
| Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults (NCT02165267) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-08-01 |
| H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo... (NCT02206464) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-07-29 |
| Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Mali (NCT02206451) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-07-16 |
| Impact of Allo- and Autoantibodies on Chronic Cardiac Allograft Function (NCT02752789) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-07-15 |
| Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults (NCT02207920) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-07-01 |
| Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations (NCT02100436) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-06-11 |
| Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995 (NCT02116764) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-06-11 |
| Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy (NCT02028403) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-06-01 |
| Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995 (NCT02082353) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-06-01 |
| Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123. (NCT02106338) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-06-01 |
| Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans (NCT02154035) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-05-31 |
| PET Imaging and Lymph Node Assessment of IRIS in People With AIDS (NCT02147405) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-05-30 |
| Challenge Model for Assessment of Human TB Immunity (NCT01868464) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-05-28 |
| Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome (NCT02130882) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-05-19 |
| Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States (NCT02153996) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-05-15 |
| Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load (NCT01933594) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-05-05 |
| Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals (NCT02151344) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-05-01 |
| Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants (NCT01827358) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-04-30 |
| Rituximab for Anti-cytokine Autoantibody-Associated Diseases (NCT01842386) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-04-29 |
| Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural Fairs (NCT02124096) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-04-25 |
| Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study (NCT02081638) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-04-18 |
| Auranofin PK Following Oral Dose Administration (NCT02089048) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-04-02 |
| ADRN Barrier/Immunoprofiling Exploratory Pilot Study (NCT02115399) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-04-01 |
| Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease (NCT02233036) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-03-26 |